Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma

References

• Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13: 325–334.
   PubMed Web of Science ®Google Scholar
• Sjo LD, Poulsen CB, Hansen M, Miiller MB, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochem-istry: identification of prognostic subgroups. E Eur J Haematol 2007; 79: 501–507.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD. Emerging prognostic factors in diffuse large B celllymphoma. Curr Opin Oncol 2004; 16: 436–441.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, RosenwaldA et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000; 40: 3503–3511.
   Google Scholar
• Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470.
   PubMed Web of Science ®Google Scholar
• Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and Bc1-6 expression in parafin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846–852.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, DelabieJ, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.
   PubMed Web of Science ®Google Scholar
• Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B cell lymphoma. Am J Clin Pathol 2001; 115: 582–588.
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna RW, Molberg KH, Kroft SH. Clinicopathologic analysis of CD10± and CD10— diffuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and bc1-2. Am J Clin Pathol 2001; 116: 183–190.
   PubMed Web of Science ®Google Scholar
• Takeshita M, Iwashita A, Kurihara K, Ikejiri K, Higashi H, Udoh T et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol 2000; 24: 1641–1649.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S et al. CD10 and Bc110 exppression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156–162
   PubMed Web of Science ®Google Scholar
• Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409–426.
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B et BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86: 45–53.
   PubMed Web of Science ®Google Scholar
• Colomo L, López-Guillermo A, Perales M, Rives S, Martinez A, Bosch F et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84.
   PubMed Web of Science ®Google Scholar
• Barrans SL, O'Connor Si, Evans PA, Davies FE, Owen RG, Haynes AP et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322–332.
   PubMed Web of Science ®Google Scholar
• Linderoth J, Ehinger M, Akerman M, Cavallin-Stahl E, Enblad G, Erlanson M, Jerkeman M. Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 2007; 79: 146–149.
   PubMed Web of Science ®Google Scholar
• Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084–2092.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Warnke RA, Montgomery K, Falini B, van de Rijn M. Analysis of MUM1IIRF4 protein ekspression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686–694.
   PubMed Web of Science ®Google Scholar
• Zhang A, Ohshima K, Sato K, Kanda M, Suzumiya J, Shimazaki K et al. Prognostic clinicopathologic factors, including immuno-logic expression in diffuse large B-cell lymphomas. Pathol Int 1999; 49: 1043–1052.
   PubMed Web of Science ®Google Scholar
• Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bc1-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001; 18: 15–22.
   PubMed Web of Science ®Google Scholar
• Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001; 42: 1089–1098.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell like diffuse large B-cell lymphoma. Am J Pathol 2004; 165: 159–166.
   PubMed Web of Science ®Google Scholar
• Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M et al. Evaluation of immunophenotype in diffuse large B cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113–1120.
   PubMed Web of Science ®Google Scholar
• Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical Classification of De Novo, Transformed, and Relapsed Diffuse Large B-Cell Lymphoma Into Germinal Center B-Cell and Nongerminal Center B-Cell Subtypes Correlates With Gene Expression Profile and Patient Survival. Arch Pathol Lab Med 2006; 130: 1819–1824.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Gun Oncol 2007; 25: 805–812.
   Web of Science ®Google Scholar
• Muris ii, Meijer CJ, Vos W, van Krieken JH, Jiva NM, Ossenkoppele GJ et al. Immunohistochemical profiling based on Bc1-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723.
   PubMed Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM et al. Prognostic impact of immunohis-tochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930–4935.
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. Rituximab plus CHOP (R-CHOP) overcomes bc1-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284.
   PubMed Web of Science ®Google Scholar
• Winter JN, Weller EA, Horning Si, Krajewska M, Variakojis D, Habermann TM et al. Prognostic significance of Bc1-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213.
   PubMed Web of Science ®Google Scholar